The University of Minnesota has been selected by the National Institutes of Health (NIH) to oversee international clinical trials of synthetic antibody therapies in a bid to treat COVID-19. TrialSite News reported the actual investigational product is known as LY-COV555, produced by a partnership between Eli Lilly and a Vancouver startup named AbCellera. Backed by the NIH study program known as ACTIV-3, the sponsor and investigators hope to showcase a powerful way to harness the power of these monoclonal antibodies to inhibit COVID-19. Due to its deep and extensive experience conducting international infectious disease studies, James Neaton’s INSIGHT network was chosen to conduct the inpatient clinical trial. The study is funded, with multiple millions, out of public funds associated with Operation Warp Speed and part of the NIH Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program. The INSIGHT network participates with the national COVID-19 Prevention Network (CoVPN).
TrialSite offers a brief breakdown of prominent COVID-19 studies in Minnesota, thanks to recent reporting by Pulitzer Prize winning Jeremy Olson of the Star Tribune.
What is the premise...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).